The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer

Completed

Conditions studied: Neoadjuvant Therapy, Chemotherapy, Hormone Replacement Therapy, Breast Cancer

In brief

In patients with breast cancer who undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy molecular breast imaging (MBI) is an accurate test for assessing response rate to neoadjuvant therapy.

Key facts

Study ID

NCT01023802

Run by

Mayo Clinic

People needed

20

Starts

2009-02-01

Expected to finish

2011-02-01

Last updated by the study team

2013-05-10

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women with breast cancer scheduled to undergo neoadjuvant chemotherapy therapy or neoadjuvant hormone therapy and who have undergone any breast imaging procedure, and in whom a repeat imaging procedure is planned prior to definite surgery. MRI of the breast for accurate tumor size evaluation is recommended but not necessarily required for study inclusion.
• Are able to return for a 3-5 week follow-up MBI study and for the final MBI study at completion of the neoadjuvant therapy.
• Patient age > 18

You may not qualify if…

• Unable to understand or sign a consent form
• Pregnant or lactating
• Physically unable to sit upright and still for 40 minutes

Where it is running

• Mayo Clinic - Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.